• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Phathom Pharmaceuticals Inc. (Amendment)

    2/12/24 4:36:25 PM ET
    $PHAT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PHAT alert in real time by email
    SC 13G/A 1 d766962dsc13ga.htm SC 13G/A SC 13G/A

     

     

    ITEM 1. Securities and Exchange Commission

    Washington, D.C. 20549

     

     

    Schedule 13G

    (Rule 13d-102)

    Information to be Included in Statements Filed Pursuant

    to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed

    Pursuant to § 240.13d-2

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    (Amendment No. 1 )*

     

     

    Phathom Pharmaceuticals, Inc.

    (Name of Issuer)

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)

    71722W107

    (CUSIP Number)

    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 71722W107    Schedule 13G    Page 1 of 17

     

     1   

    Names of Reporting Persons

     

    The Carlyle Group Inc.

     2   

    Check the Appropriate Box if a Member of a Group

    (a) ☐  (b) ☐

     

     3   

    SEC Use Only

     

     4   

    Citizenship or Place of Organization

     

    Delaware

    Number of Shares Beneficially  Owned by Each Reporting Person

    With

        5   

    Sole Voting Power

     

    0

        6   

    Shared Voting Power

     

    3,496,808

        7   

    Sole Dispositive Power

     

    0

        8   

    Shared Dispositive Power

     

    3,496,808

     9   

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    3,496,808

    10   

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

    Not Applicable

    11   

    Percent of Class Represented by Amount in Row 9

     

    6.1%

    12   

    Type of Reporting Person

     

    CO


    CUSIP No. 71722W107    Schedule 13G    Page 2 of 17

     

     1   

    Names of Reporting Persons

     

    Carlyle Holdings I GP Inc.

     2   

    Check the Appropriate Box if a Member of a Group

    (a) ☐  (b) ☐

     

     3   

    SEC Use Only

     

     4   

    Citizenship or Place of Organization

     

    Delaware

    Number of Shares Beneficially  Owned by Each Reporting Person

    With

        5   

    Sole Voting Power

     

    0

        6   

    Shared Voting Power

     

    3,496,808

        7   

    Sole Dispositive Power

     

    0

        8   

    Shared Dispositive Power 

     

    3,496,808

     9   

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    3,496,808

    10   

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

    Not Applicable

    11   

    Percent of Class Represented by Amount in Row 9

     

    6.1%

    12   

    Type of Reporting Person

     

    CO


    CUSIP No. 71722W107    Schedule 13G    Page 3 of 17

     

     1   

    Names of Reporting Persons

     

    Carlyle Holdings I GP Sub L.L.C.

     2   

    Check the Appropriate Box if a Member of a Group

    (a) ☐  (b) ☐

     

     3   

    SEC Use Only

     

     4   

    Citizenship or Place of Organization

     

    Delaware

    Number of Shares Beneficially  Owned by Each Reporting Person

    With

        5   

    Sole Voting Power

     

    0

        6   

    Shared Voting Power

     

    3,496,808

        7   

    Sole Dispositive Power

     

    0

        8   

    Shared Dispositive Power

     

    3,496,808

     9   

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    3,496,808

    10   

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

    Not Applicable

    11   

    Percent of Class Represented by Amount in Row 9

     

    6.1%

    12   

    Type of Reporting Person

     

    OO (Limited Liability Company)


    CUSIP No. 71722W107    Schedule 13G    Page 4 of 17

     

     1   

    Names of Reporting Persons

     

    Carlyle Holdings I L.P.

     2   

    Check the Appropriate Box if a Member of a Group

    (a) ☐  (b) ☐

     

     3   

    SEC Use Only

     

     4   

    Citizenship or Place of Organization

     

    Delaware

    Number of Shares Beneficially  Owned by Each Reporting Person

    With

        5   

    Sole Voting Power

     

    0

        6   

    Shared Voting Power

     

    3,496,808

        7   

    Sole Dispositive Power

     

    0

        8   

    Shared Dispositive Power

     

    3,496,808

     9   

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    3,496,808

    10   

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

    Not Applicable

    11   

    Percent of Class Represented by Amount in Row 9

     

    6.1%

    12   

    Type of Reporting Person

     

    PN


    CUSIP No. 71722W107    Schedule 13G    Page 5 of 17

     

     1   

    Names of Reporting Persons

     

    CG Subsidiary Holdings L.L.C.

     2   

    Check the Appropriate Box if a Member of a Group

    (a) ☐  (b) ☐

     

     3   

    SEC Use Only

     

     4   

    Citizenship or Place of Organization

     

    Delaware

    Number of Shares Beneficially  Owned by Each Reporting Person

    With

        5   

    Sole Voting Power

     

    0

        6   

    Shared Voting Power

     

    3,496,808

        7   

    Sole Dispositive Power

     

    0

        8   

    Shared Dispositive Power

     

    3,496,808

     9   

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    3,496,808

    10   

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

    Not Applicable

    11   

    Percent of Class Represented by Amount in Row 9

     

    6.1%

    12   

    Type of Reporting Person

     

    OO (Limited Liability Company)


    CUSIP No. 71722W107    Schedule 13G    Page 6 of 17

     

     1   

    Names of Reporting Persons

     

    TC Group, L.L.C.

     2   

    Check the Appropriate Box if a Member of a Group

    (a) ☐  (b) ☐

     

     3   

    SEC Use Only

     

     4   

    Citizenship or Place of Organization

     

    Delaware

    Number of Shares Beneficially  Owned by Each Reporting Person

    With

        5   

    Sole Voting Power

     

    0

        6   

    Shared Voting Power

     

    3,496,808

        7   

    Sole Dispositive Power

     

    0

        8   

    Shared Dispositive Power

     

    3,496,808

     9   

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    3,496,808

    10   

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

    Not Applicable

    11   

    Percent of Class Represented by Amount in Row 9

     

    6.1%

    12   

    Type of Reporting Person

     

    OO (Limited Liability Company)


    CUSIP No. 71722W107    Schedule 13G    Page 7 of 17

     

     1   

    Names of Reporting Persons

     

    Carlyle Investment Management L.L.C.

     2   

    Check the Appropriate Box if a Member of a Group

    (a) ☐  (b) ☐

     

     3   

    SEC Use Only

     

     4   

    Citizenship or Place of Organization

     

    Delaware

    Number of Shares Beneficially  Owned by Each Reporting Person

    With

        5   

    Sole Voting Power

     

    0

        6   

    Shared Voting Power

     

    3,496,808

        7   

    Sole Dispositive Power

     

    0

        8   

    Shared Dispositive Power

     

    3,496,808

     9   

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    3,496,808

    10   

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

    Not Applicable

    11   

    Percent of Class Represented by Amount in Row 9

     

    6.1%

    12   

    Type of Reporting Person

     

    OO (Limited Liability Company)


    CUSIP No. 71722W107    Schedule 13G    Page 8 of 17

     

     1   

    Names of Reporting Persons

     

    Carlyle Genesis UK LLC

     2   

    Check the Appropriate Box if a Member of a Group

    (a) ☐  (b) ☐

     

     3   

    SEC Use Only

     

     4   

    Citizenship or Place of Organization

     

    Delaware

    Number of Shares Beneficially  Owned by Each Reporting Person

    With

        5   

    Sole Voting Power

     

    0

        6   

    Shared Voting Power

     

    3,496,808

        7   

    Sole Dispositive Power

     

    0

        8   

    Shared Dispositive Power

     

    3,496,808

     9   

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    3,496,808

    10   

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

    Not Applicable

    11   

    Percent of Class Represented by Amount in Row 9

     

    6.1%

    12   

    Type of Reporting Person

     

    OO (Limited Liability Company)


    CUSIP No. 71722W107    Schedule 13G    Page 9 of 17

     

     1   

    Names of Reporting Persons

     

    Abingworth LLP

     2   

    Check the Appropriate Box if a Member of a Group

    (a) ☐  (b) ☐

     

     3   

    SEC Use Only

     

     4   

    Citizenship or Place of Organization

     

    England and Wales

    Number of Shares Beneficially  Owned by Each Reporting Person

    With

        5   

    Sole Voting Power

     

    0

        6   

    Shared Voting Power

     

    3,496,808

        7   

    Sole Dispositive Power

     

    0

        8   

    Shared Dispositive Power

     

    3,496,808

     9   

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    3,496,808

    10   

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

    Not Applicable

    11   

    Percent of Class Represented by Amount in Row 9

     

    6.1%

    12   

    Type of Reporting Person

     

    PN


    CUSIP No. 71722W107    Schedule 13G    Page 10 of 17

     

     1   

    Names of Reporting Persons

     

    Abingworth Bioventures 8 LP

     2   

    Check the Appropriate Box if a Member of a Group

    (a) ☐  (b) ☐

     

     3   

    SEC Use Only

     

     4   

    Citizenship or Place of Organization

     

    England and Wales

    Number of Shares Beneficially  Owned by Each Reporting Person

    With

        5   

    Sole Voting Power

     

    0

        6   

    Shared Voting Power

     

    2,061,702

        7   

    Sole Dispositive Power

     

    0

      

     8

      

    Shared Dispositive Power

     

    2,061,702

     9   

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    2,061,702

    10   

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

    Not Applicable

    11   

    Percent of Class Represented by Amount in Row 9

     

    3.6%

    12   

    Type of Reporting Person

     

    PN


    CUSIP No. 71722W107    Schedule 13G    Page 11 of 17

     

     1   

    Names of Reporting Persons

     

    Abingworth Bioventures VII LP

     2   

    Check the Appropriate Box if a Member of a Group

    (a) ☐  (b) ☐

     

     3   

    SEC Use Only

     

     4   

    Citizenship or Place of Organization

     

    England and Wales

    Number of Shares Beneficially  Owned by Each Reporting Person

    With

        5   

    Sole Voting Power

     

    0

        6   

    Shared Voting Power

     

    1,435,106

        7   

    Sole Dispositive Power

     

    0

        8   

    Shared Dispositive Power

     

    1,435,106

     9   

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,435,106

    10   

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

    Not Applicable

    11   

    Percent of Class Represented by Amount in Row 9

     

    2.5%

    12   

    Type of Reporting Person

     

    PN


    CUSIP No. 71722W107    Schedule 13G    Page 12 of 17

     

    ITEM 2.    (a)    Name of Issuer:
         

    Phathom Pharmaceuticals, Inc. (the “Issuer”).

       (b)    Address of Issuer’s Principal Executive Offices:
         

    100 Campus Drive, Suite 102, Florham Park, NJ 07932

    ITEM 3.    (a)    Name of Person Filing:
         

    Each of the following is hereinafter individually referred to as a “Reporting Person” and collectively as the “Reporting Persons.” This statement is filed on behalf of:

         

    The Carlyle Group Inc.

         

    Carlyle Holdings I GP Inc.

         

    Carlyle Holdings I GP Sub L.L.C.

         

    Carlyle Holdings I L.P.

         

    CG Subsidiary Holdings L.L.C.

         

    TC Group, L.L.C.

         

    Carlyle Investment Management L.L.C.

         

    Carlyle Genesis UK LLC

         

    Abingworth LLP

         

    Abingworth Bioventures 8 LP

         

    Abingworth Bioventures VII LP

       (b)    Address or Principal Business Office:
         

    The principal business address of each of Abingworth LLP, Abingworth Bioventures 8 LP and Abingworth Bioventures VII LP is 38 Jermyn Street, London, SW1Y 6DN, England, United Kingdom. The principal business address of each of the other Reporting Persons is c/o The Carlyle Group, 1001 Pennsylvania Ave. NW, Suite 220 South, Washington, DC 20004-2505.

       (c)    Citizenship of each Reporting Person is:
         

    Each of Abingworth LLP, Abingworth Bioventures 8 LP and Abingworth Bioventures VII LP is organized under the laws of England and Wales. Each of the other Reporting Persons is organized under the laws of the State of Delaware.

       (d)    Title of Class of Securities:
         

    Common Stock, par value $0.0001 per share (“Common Stock”).

       (e)    CUSIP Number:
         

    71722W107


    CUSIP No. 71722W107    Schedule 13G    Page 13 of 17

     

    ITEM 4.

    Not applicable.

     

    ITEM 5.

    Ownership.

    (a-c)

    The ownership information presented below represents beneficial ownership of Common Stock of the Issuer as of November 7, 2023, based upon 57,252,519 shares of Common Stock outstanding, as disclosed in the Issuer’s Quarterly Report on Form 10-Q as filed with the Securities and Exchange Commission on November 9, 2023.

     

    Reporting Person

       Amount
    beneficially
    owned
         Percent
    of class
        Sole
    power to
    vote or to
    direct the
    vote
         Shared
    power to
    vote or to
    direct the
    vote
         Sole power
    to dispose
    or to direct
    the
    disposition
         Shared
    power to
    dispose or to
    direct the
    disposition
     

    The Carlyle Group Inc.

         3,496,808        6.1 %      0        3,496,808        0        3,496,808  

    Carlyle Holdings I GP Inc.

         3,496,808        6.1 %      0        3,496,808        0        3,496,808  

    Carlyle Holdings I GP Sub L.L.C.

         3,496,808        6.1 %      0        3,496,808        0        3,496,808  

    Carlyle Holdings I L.P.

         3,496,808        6.1 %      0        3,496,808        0        3,496,808  

    CG Subsidiary Holdings L.L.C.

         3,496,808        6.1 %      0        3,496,808        0        3,496,808  

    TC Group, L.L.C.

         3,496,808        6.1 %      0        3,496,808        0        3,496,808  

    Carlyle Investment Management L.L.C.

         3,496,808        6.1 %      0        3,496,808        0        3,496,808  

    Carlyle Genesis UK LLC

         3,496,808        6.1 %      0        3,496,808        0        3,496,808  

    Abingworth LLP

         3,496,808        6.1 %      0        3,496,808        0        3,496,808  

    Abingworth Bioventures 8 LP

         2,061,702        3.6 %      0        2,061,702        0        2,061,702  

    Abingworth Bioventures VII LP

         1,435,106        2.5 %      0        1,435,106        0        1,435,106  

    Abingworth Bioventures 8 LP is the record holder of 2,061,702 shares of Common Stock and Abingworth Bioventures VII LP is the record holder of 1,435,106 shares of Common Stock.

    The Carlyle Group Inc., which is a publicly traded entity listed on Nasdaq, is the sole shareholder of Carlyle Holdings I GP Inc., which is the sole member of Carlyle Holdings I GP Sub L.L.C., which is the general partner of Carlyle Holdings I L.P., which, with respect to the securities reported herein, is the managing member of CG Subsidiary Holdings L.L.C., which is the managing member of TC Group, L.L.C., which is the managing member of Carlyle Investment Management L.L.C., which is the sole member of Carlyle Genesis UK LLC, which is the principal member of


    CUSIP No. 71722W107    Schedule 13G    Page 14 of 17

     

    Abingworth LLP. Each of Abingworth Bioventures 8 LP and Abingworth Bioventures VII LP has delegated to Abingworth LLP all investment and dispositive power over the securities held of record by them. Accordingly, each of the foregoing entities may be deemed to share beneficial ownership of the securities held of record by Abingworth Bioventures 8 LP and Abingworth Bioventures VII LP, but each disclaims beneficial ownership of such securities.

     

    ITEM 6.

    Ownership of Five Percent or Less of a Class.

    Not applicable.

     

    ITEM 7.

    Ownership of More than Five Percent on Behalf of Another Person.

    Not applicable.

     

    ITEM 8.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

    Not applicable.

     

    ITEM 9.

    Identification and Classification of Members of the Group.

    Not applicable.

     

    ITEM 10.

    Notice of Dissolution of Group.

    Not applicable.

     

    ITEM 11.

    Certification.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.


    CUSIP No. 71722W107    Schedule 13G    Page 15 of 17

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date: February 12, 2024

     

    The Carlyle Group Inc.
    By:   /s/ Anne Frederick, attorney-in-fact
    Name:   John C. Redett
    Title:   Chief Financial Officer
    Carlyle Holdings I GP Inc.
    By:   /s/ Anne Frederick, attorney-in-fact
    Name:   John C. Redett
    Title:   Managing Director and Chief Financial Officer
    Carlyle Holdings I GP Sub L.L.C.
    By: Carlyle Holdings I GP Inc., its sole member
    By:   /s/ Anne Frederick, attorney-in-fact
    Name:   John C. Redett
    Title:   Managing Director and Chief Financial Officer
    Carlyle Holdings I L.P.
    By:   /s/ Anne Frederick, attorney-in-fact
    Name:   John C. Redett
    Title:   Managing Director
    CG Subsidiary Holdings L.L.C.
    By:   /s/ Anne Frederick, attorney-in-fact
    Name:   John C. Redett
    Title:   Managing Director
    TC Group, L.L.C.
    By:   /s/ Anne Frederick, attorney-in-fact
    Name:   John C. Redett
    Title:   Managing Director


    CUSIP No. 71722W107    Schedule 13G    Page 16 of 17

     

    Carlyle Investment Management L.L.C.
    By:   /s/ Anne Frederick, attorney-in-fact
    Name:   John C. Redett
    Title:   Chief Financial Officer
    Carlyle Genesis UK LLC
    By: Carlyle Investment Management L.L.C., its sole member
    By:   /s/ Anne Frederick, attorney-in-fact
    Name:   John C. Redett
    Title:   Chief Financial Officer
    Abingworth LLP
    By:   /s/ John Heard
    Name:   John Heard
    Title:   Authorized Signatory
    Abingworth Bioventures 8 LP
    By:   /s/ John Heard
    Name:   John Heard
    Title:   Authorized Signatory
    Abingworth Bioventures VII LP
    By:   /s/ John Heard
    Name:   John Heard
    Title:   Authorized Signatory


    CUSIP No. 71722W107    Schedule 13G    Page 17 of 17

     

    LIST OF EXHIBITS

     

    Exhibit No.

      

    Description

    24    Power of Attorney.
    99    Joint Filing Agreement (previously filed).
    Get the next $PHAT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PHAT

    DatePrice TargetRatingAnalyst
    2/14/2025$23.00Overweight
    Cantor Fitzgerald
    5/3/2024$24.00Buy
    Stifel
    1/5/2024$23.00 → $26.00Buy
    Needham
    8/9/2023$28.00Buy
    H.C. Wainwright
    5/11/2023In-line → Outperform
    Evercore ISI
    3/13/2023$21.00Buy
    Craig Hallum
    10/21/2022$16.00Buy
    Jefferies
    5/6/2022Outperform → In-line
    Evercore ISI
    More analyst ratings

    $PHAT
    Financials

    Live finance-specific insights

    See more
    • Phathom Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

      VOQUEZNA launch momentum continues with over 390,000 prescriptions filled to date, written by more than 23,600 healthcare providersNet revenues of $28.5 million reported for Q1Filled VOQUEZNA prescriptions increased ~8% in Q1 over the prior quarter despite seasonal headwindsStrategic cost reductions and executive leadership changes implemented to support sustainable revenue growth and achieve profit from operations, excluding stock-based compensation, in 2026Management to host conference call today, May 1, 2025, at 8:00 a.m. ET FLORHAM PARK, N.J., May 01, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commerciali

      5/1/25 7:00:41 AM ET
      $ITCI
      $PHAT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Phathom Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide Business Update on Thursday, May 1, 2025

      • Management to host conference call on Thursday, May 1, 2025, at 8:00 am EDT FLORHAM PARK, N.J., April 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that it will host a live webcast at 8:00 am EDT on Thursday, May 1, 2025, to report its first quarter 2025 financial results and provide a business update. A live webcast and additional information about the presentation can be accessed on the Events & Presentations section of the Phathom website at https://investors.phathompharma.com/news-events/events-and-presentations. A recordi

      4/23/25 8:00:22 AM ET
      $PHAT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

      VOQUEZNA® (vonoprazan) generated $55.3 million in 2024 net revenues in its first full year of launch, driven by strong demand, including $29.7 million in Q4, an 81% increase from Q3Over 300,000 filled prescriptions for VOQUEZNA products, launch-to-date, approximately a 110% increase since last earnings reportPhase 2 EoE trial for VOQUEZNA nearing initiation, with first patient enrollment planned for Q2 2025Management to host conference call today, March 6, 2025, at 8:30 a.m. ET FLORHAM PARK, N.J., March 06, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointesti

      3/6/25 8:00:01 AM ET
      $PHAT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PHAT
    SEC Filings

    See more
    • SEC Form 10-Q filed by Phathom Pharmaceuticals Inc.

      10-Q - Phathom Pharmaceuticals, Inc. (0001783183) (Filer)

      5/1/25 7:05:22 AM ET
      $PHAT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Phathom Pharmaceuticals Inc.

      8-K - Phathom Pharmaceuticals, Inc. (0001783183) (Filer)

      5/1/25 7:05:17 AM ET
      $PHAT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Phathom Pharmaceuticals Inc.

      SCHEDULE 13G/A - Phathom Pharmaceuticals, Inc. (0001783183) (Subject)

      4/24/25 2:30:31 PM ET
      $PHAT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PHAT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Topper James N bought $14,609 worth of shares (3,780 units at $3.86) (SEC Form 4)

      4 - Phathom Pharmaceuticals, Inc. (0001783183) (Issuer)

      5/23/25 4:06:35 PM ET
      $PHAT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Topper James N bought $24,462 worth of shares (7,420 units at $3.30) (SEC Form 4)

      4 - Phathom Pharmaceuticals, Inc. (0001783183) (Issuer)

      5/15/25 4:17:38 PM ET
      $PHAT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Topper James N bought $152,917 worth of shares (48,203 units at $3.17) (SEC Form 4)

      4 - Phathom Pharmaceuticals, Inc. (0001783183) (Issuer)

      5/13/25 4:13:04 PM ET
      $PHAT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PHAT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Topper James N bought $14,609 worth of shares (3,780 units at $3.86) (SEC Form 4)

      4 - Phathom Pharmaceuticals, Inc. (0001783183) (Issuer)

      5/23/25 4:06:35 PM ET
      $PHAT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Principal Accounting Officer Breedlove Robert Charles

      4 - Phathom Pharmaceuticals, Inc. (0001783183) (Issuer)

      5/21/25 5:17:36 PM ET
      $PHAT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Topper James N bought $24,462 worth of shares (7,420 units at $3.30) (SEC Form 4)

      4 - Phathom Pharmaceuticals, Inc. (0001783183) (Issuer)

      5/15/25 4:17:38 PM ET
      $PHAT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PHAT
    Leadership Updates

    Live Leadership Updates

    See more
    • Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      FLORHAM PARK, N.J., May 01, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced that, in connection with the appointment of Jonathan Bentley as Senior Vice President, Head of Sales, the Company's Board of Directors has approved the grant of inducement awards. On May 1, 2025, the Company's Board of Directors granted inducement awards to Mr. Bentley under the Company's 2025 Employment Inducement Incentive Award Plan (the "Inducement Plan"). Mr. Bentley was granted a non-qualified stock option to purchase 79,365 shares of Phathom common

      5/1/25 4:15:59 PM ET
      $PHAT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Frazier Life Sciences Appoints Aditya Kohli to Partner

      Frazier Life Sciences (FLS), a longstanding investment firm focused on innovative therapeutics, today announced the appointment of Aditya Kohli, Ph.D., to Partner. Since joining FLS in 2016, Dr. Kohli has played a foundational role in company creation, co-founding six life sciences companies, including HilleVax (NASDAQ:HLVX, IPO in 2022)), Phathom Pharmaceuticals (NASDAQ:PHAT, IPO in 2019)), and Scout Bio (acquired by Ceva Santé Animale). He previously acted as Chief Business Officer at Phathom, Chief Operating Officer at HilleVax, and served on the Board of Scout Bio. He currently serves on the Board of HilleVax. "Aditya has been a valued member of the FLS team, and we are thrilled to se

      4/17/25 8:00:00 AM ET
      $HLVX
      $PHAT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Phathom Pharmaceuticals Appoints Ted Schroeder to its Board of Directors

      FLORHAM PARK, N.J., April 16, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced the appointment of Ted Schroeder to its Board of Directors. Mr. Schroeder brings more than three decades of experience leading innovative biopharmaceutical companies and has a strong track record of building and scaling commercial organizations, bringing new therapies to market, and successfully guiding companies through key business milestones and strategic transactions. "We are pleased to welcome Ted to the Phathom Board during a pivotal period for the com

      4/16/25 8:00:46 AM ET
      $CDTX
      $PHAT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $PHAT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

      FLORHAM PARK, N.J., May 15, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today that the company is scheduled to participate in the following investor conferences in May and June: H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ in New York, NYDate: Tuesday, May 20, 2025Live Webcast: 4:00 p.m. ETCompany to participate in one-on-one meetings throughout the conference Jefferies Global Healthcare Conference in New York, NYDate: Thursday, June 5, 2025Live Webcast: 9:55 a.m. ETCompany to participate in one-on-one meetin

      5/15/25 7:59:54 AM ET
      $PHAT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      FLORHAM PARK, N.J., May 01, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced that, in connection with the appointment of Jonathan Bentley as Senior Vice President, Head of Sales, the Company's Board of Directors has approved the grant of inducement awards. On May 1, 2025, the Company's Board of Directors granted inducement awards to Mr. Bentley under the Company's 2025 Employment Inducement Incentive Award Plan (the "Inducement Plan"). Mr. Bentley was granted a non-qualified stock option to purchase 79,365 shares of Phathom common

      5/1/25 4:15:59 PM ET
      $PHAT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Phathom Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

      VOQUEZNA launch momentum continues with over 390,000 prescriptions filled to date, written by more than 23,600 healthcare providersNet revenues of $28.5 million reported for Q1Filled VOQUEZNA prescriptions increased ~8% in Q1 over the prior quarter despite seasonal headwindsStrategic cost reductions and executive leadership changes implemented to support sustainable revenue growth and achieve profit from operations, excluding stock-based compensation, in 2026Management to host conference call today, May 1, 2025, at 8:00 a.m. ET FLORHAM PARK, N.J., May 01, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commerciali

      5/1/25 7:00:41 AM ET
      $ITCI
      $PHAT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PHAT
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for VOQUEZNA issued to PHATHOM PHARMACEUTICALS INC

      Submission status for PHATHOM PHARMACEUTICALS INC's drug VOQUEZNA (ORIG-1) with active ingredient VONOPRAZAN FUMARATE has changed to 'Approval' on 07/17/2024. Application Category: NDA, Application Number: 218710, Application Classification: Type 9 - New Indication Submitted as Distinct NDA, Consolidated with Original NDA after Approval

      7/18/24 10:52:01 AM ET
      $PHAT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for VOQUEZNA TRIPLE PAK issued to PHATHOM PHARMACEUTICALS, INC

      Submission status for PHATHOM PHARMACEUTICALS, INC's drug VOQUEZNA TRIPLE PAK (ORIG-1) with active ingredient AMOXICILLIN; CLARITHROMYCIN; VONOPRAZAN has changed to 'Approval' on 05/03/2022. Application Category: NDA, Application Number: 215152, Application Classification: Type 1 - New Molecular Entity and Type 4 - New Combination

      5/11/22 10:51:07 AM ET
      $PHAT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for VOQUEZNA DUAL PAK issued to PHATHOM PHARMACEUTICALS, INC

      Submission status for PHATHOM PHARMACEUTICALS, INC's drug VOQUEZNA DUAL PAK (ORIG-1) with active ingredient AMOXICILLIN; VONOPRAZAN has changed to 'Approval' on 05/03/2022. Application Category: NDA, Application Number: 215153, Application Classification: Type 5 - New Formulation or New Manufacturer

      5/11/22 10:17:03 AM ET
      $PHAT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PHAT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald initiated coverage on Phathom Pharmaceuticals with a new price target

      Cantor Fitzgerald initiated coverage of Phathom Pharmaceuticals with a rating of Overweight and set a new price target of $23.00

      2/14/25 7:06:18 AM ET
      $PHAT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stifel initiated coverage on Phathom Pharmaceuticals with a new price target

      Stifel initiated coverage of Phathom Pharmaceuticals with a rating of Buy and set a new price target of $24.00

      5/3/24 7:37:39 AM ET
      $PHAT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Needham reiterated coverage on Phathom Pharmaceuticals with a new price target

      Needham reiterated coverage of Phathom Pharmaceuticals with a rating of Buy and set a new price target of $26.00 from $23.00 previously

      1/5/24 8:05:02 AM ET
      $PHAT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PHAT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Phathom Pharmaceuticals Inc.

      SC 13G - Phathom Pharmaceuticals, Inc. (0001783183) (Subject)

      11/4/24 11:20:50 AM ET
      $PHAT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Phathom Pharmaceuticals Inc.

      SC 13D/A - Phathom Pharmaceuticals, Inc. (0001783183) (Subject)

      8/22/24 4:05:55 PM ET
      $PHAT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Phathom Pharmaceuticals Inc. (Amendment)

      SC 13D/A - Phathom Pharmaceuticals, Inc. (0001783183) (Subject)

      6/6/24 1:59:25 PM ET
      $PHAT
      Biotechnology: Pharmaceutical Preparations
      Health Care